COMPASS Pathways

Compass Pathways Plc functions as an investment holding company. It operates through its subsidiaries which provide mental health care services. The company was founded by Goldsmith George Jay and Malievaskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Compass Pathways Plc is an investment holding company. It operates through its subsidiaries which provide mental health care services. The company was founded by Goldsmith George Jay and Malievaskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

LONDON, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference at 10:25 am ET on November 30, 2023.

Compass Pathways to participate in upcoming Evercore investor conference

LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the initiation of the UK component of its phase 3 program of investigational COMP360 psilocybin treatment in treatment-resistant depression (TRD). The research will take place in multiple sites in the UK, including at the Centre for Mental Health Research and Innovation (“the Centre”) in London, which officially opened today.

Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center

COMPASS Pathways plc (NASDAQ:CMPS ) Q3 2023 Results Conference Call November 2, 2023 8:00 AM ET Company Participants Stephen Schultz - SVP, IR Kabir Nath - CEO Mary-Rose Hughes - Interim CFO Dr. Guy Goodwin - Chief Medical Officer Conference Call Participants Ritu Baral - TD Cohen Charles Duncan - Cantor François Brisebois - Oppenheimer Patrick Trucchio - H.C. Wainright Michael Okunewitch - Maxim Group Sumant Kulkarni - Canaccord Genuity Gavin Clark-Gartner - Evercore ISI Thomas Shrader - BTIG Operator Good day, ladies and gentlemen, and welcome to the COMPASS Pathways Third Quarter 2023 Conference Call.

COMPASS Pathways plc (CMPS) Q3 2023 Earnings Call Transcript

LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2023 and provided an update on recent progress across its business.

COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights

LONDON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS” or the “company”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that Mike Falvey, Chief Financial Officer, will depart the company on November 3, 2023, to pursue other opportunities. Mary-Rose Hughes, current Vice President of Finance at COMPASS, will assume the role of interim CFO effective today. COMPASS has begun a search to select a permanent Chief Financial Officer.

COMPASS Pathways announces CFO transition

LONDON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter 2023, and provide an update on recent business developments on November 2, 2023.

COMPASS Pathways plc to Announce Third Quarter 2023 Financial Results on November 2, 2023

Psychedelic stocks are on the rise. Despite the stigma surrounding psychedelics for personal use, controlled medical experiments indicate their usefulness for treating a variety of conditions.

Don't Miss the Boom: 3 Psychedelic Stocks Set to Explode Higher

LONDON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Daphne Karydas to its Board of Directors, effective September 18, 2023. Ms. Karydas is President and Chief Financial Officer at Flare Therapeutics Inc., a privately held biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases.

COMPASS Pathways appoints Daphne Karydas to its Board of Directors

COMPASS Pathways PLC Sponsored ADR (CMPS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, CMPS's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.

COMPASS Pathways PLC Sponsored ADR (CMPS) Just Flashed Golden Cross Signal: Do You Buy?

LONDON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a new paper in Pyschopharmacology, which showed the results of a retrospective study that evaluates the potential of its AI technologies to support investigational COMP360 psilocybin treatment in treatment-resistant depression (TRD). The paper was published on August 22, 2023.

COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression

LONDON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the following investor conferences:

COMPASS Pathways to participate in upcoming September investor conferences

Beam Therapeutics

908 Devices

Cathie Wood is an icon in the world of disruptive tech. Her firm ARK Invest holds positions in Beam Therapeutics, COMPASS Pathways, and 908 Devices.

3 Cathie Wood Stocks With Parabolic Growth Potential, According to Wall Street

LONDON, Aug. 16, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has entered into a securities purchase agreement with a select group of healthcare specialist investors for the private placement of (i) 16,076,750 American Depositary Shares (“ADSs”) representing 16,076,750 ordinary shares, and (ii) warrants to purchase up to 16,076,750 ADSs (representing 16,076,750 ordinary shares) (the “Warrants”) at a purchase price of approximately $7.78 per ADS and accompanying Warrant to purchase one ADS. Each Warrant will have an exercise price of $9.93 per ADS, representing a 30% premium to the last sale price. The financing is expected to close on August 18, 2023, subject to customary closing conditions.

COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors

COMPASS Pathways plc (NASDAQ:CMPS ) Q2 2023 Earnings Conference Call August 3, 2023 8:00 AM ET Company Participants Stephen Schultz - Senior Vice President of Investor Relations Kabir Nath - Chief Executive Officer Guy Goodwin - Chief Medical Officer Mike Falvey - Chief Financial Officer Conference Call Participants Ritu Baral - Cowen and Company, LLC Charles Duncan - Cantor Fitzgerald Patrick Trucchio - H.C. Wainwright & Co, LLC Francois Brisebois - Oppenheimer & Co. Elemer Piros - EF Hutton Thomas Shrader - BTIG Kyle Qian - Canaccord Genuity Michael Okunewitch - Maxim Group LLC Operator Good day, ladies and gentlemen, and welcome to the COMPASS Pathways Second Quarter 2023 Conference Call.

COMPASS Pathways plc (CMPS) Q2 2023 Earnings Call Transcript

LONDON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, reported its financial results for the second quarter 2023 and gave an update on recent progress across its business.

COMPASS Pathways Announces Second Quarter 2023 Financial Results and Business Highlights

LONDON, July 31, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2023, and provide an update on recent business developments on August 3, 2023.

COMPASS Pathways plc to announce second quarter 2023 financial results on August 3, 2023

COMP360 appears to be compatible with certain antidepressant medications. That's contrary to some prior assumptions, so it's a pleasant surprise.

This Unexpected Development Is Yet Another Green Flag for Compass Pathways Stock

COMP360 psilocybin treatment shows potential in exploratory open-label investigator-initiated study in anorexia nervosa COMP360 psilocybin treatment shows potential in exploratory open-label investigator-initiated study in anorexia nervosa

First clinical study results of psilocybin treatment in anorexia nervosa published in Nature Medicine

LONDON, July 17, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that positive data from an open-label phase 2 clinical trial of investigational COMP360 psilocybin in addition to daily selective serotonin reuptake inhibitors (SSRIs) in treatment-resistant depression has been published online in the peer reviewed Nature journal, Neuropsychopharmacology .

COMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2 clinical trial of COMP360 psilocybin alongside antidepressants in Nature journal, Neuropsychopharmacology

Atai Life Sciences BV

Cybin

Alex Carchidi returns to update investors on the psychedelics industry. Collapse, consolidation, and why you shouldn't bet on just 1 stock.

Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets.

A review of recent research suggests that the testing methods may have led to overly optimistic expectations. A competitive drug has been approved and appears to be making excellent commercial headway. COMPASS Pathways is short on cash but has major investment house backing.

COMPASS: The Landscape Is Changing Quickly; Risk Is Up And Potential Down

Will tough times continue for psychedelic stocks? Analyst Alex Carchidi shares his views on the sector and specific stocks like Compass Pathways, Atai and Cybin.

Psychedelic Stocks: Don't Bet On Just 1 Company

LONDON, July 13, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a paper in the American Journal of Psychiatry that examines the definition of "psychedelic-assisted psychotherapy" using psilocybin and offers a new way of thinking about and describing this potential new treatment in psychiatry. The article is authored by leading psychiatrists and researchers, including COMPASS's Chief Medical Officer, Dr. Guy Goodwin, and Co-founder and COMPASS board member, Dr. Ekaterina Malievskaia.

Opinion paper calls for clarity on the definition of “psychedelic-assisted therapy” using psilocybin

LONDON, July 06, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that the American Medical Association has released the language of its new Current Procedural Terminology (CPT®) III code for Continuous In-Person Monitoring and Intervention During Psychedelic Medication Therapy. The code will go into effect and will be published in the CPT manual on January 1, 2024. The approval of the new category CPT III code, announced in May following an application by COMPASS and MAPS Public Benefit Corporation (MAPS PBC), was supported by the American Psychiatric Association, American Psychological Association and the National Association of Social Workers. Once effective, the new code will provide a mechanism to track and report the delivery of psychedelic treatments and will cover, subject to FDA approval, COMPASS's COMP360 psilocybin treatment, which is currently in late-stage development for treatment-resistant depression, and MAPS' MDMA-AT for post-traumatic stress disorder. The new code, reported in increments of one hour, will cover multiple psychedelic compounds with psychological support models, if approved, as well as variable staffing structures and numbers and credentials of qualified healthcare professionals (QHPs). It will also offer a sub-code for the involvement of non-QHP clinical staff. The use of this category III tracking code will be key to developing optimal permanent and valued category I codes for psychedelic therapies as close as possible to their potential FDA approval.

American Medical Association Releases Language of First New Current Procedural Terminology Code for Psychedelic Therapies

LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that the Company has entered into a term loan agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $50 million.

News for COMPASS Pathways Stock (CMPS)